A multicenter, randomized phase 3 study of asciminib (ABL001) vs bosutinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with ≥2 TKIs Meeting Abstract
| Authors: | Mauro, M. J.; Hochhaus, A.; Boquimpani, C.; Minami, Y.; Allepuz, A.; Polydoros, F.; Bédoucha, V.; Aimone, P.; Réa, D. |
| Abstract Title: | A multicenter, randomized phase 3 study of asciminib (ABL001) vs bosutinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with ≥2 TKIs |
| Meeting Title: | 7th Annual Meeting of the Society of Hematologic Oncology (SOHO 2019) |
| Keywords: | clinical trial; cml; tyrosine kinase inhibitor; chronic; myelogenous leukemia; asciminib |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 19 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2019 Sep 11-14 |
| Meeting Location: | Houston, TX |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2019-09-01 |
| Start Page: | S286 |
| End Page: | S287 |
| Language: | English |
| ACCESSION: | WOS:000483480700267 |
| DOI: | 10.1016/j.clml.2019.07.230 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: CML-040 -- Source: Wos |
